Publications by authors named "S Sevcikova"
Article Synopsis
- Multiple myeloma (MM) is a complex blood cancer characterized by the expansion of abnormal plasma cells in the bone marrow, resulting in symptoms like bone damage, low blood cell counts, and kidney issues.
- Despite improved treatments, the disease often relapses, and its development is linked to genomic instability, particularly a phenomenon called chromothripsis, which causes major chromosome shattering and rearrangement.
- This review aims to summarize key chromosomal abnormalities in MM, with an emphasis on how chromothripsis contributes to the disease's complexity and opens up potential avenues for better diagnostics and understanding of its underlying mechanisms.
Multiple myeloma (MM) is the second most prevalent hematological malignancy, characterized by infiltration of the bone marrow by malignant plasma cells. Extramedullary disease (EMD) represents a more aggressive condition involving the migration of a subclone of plasma cells to paraskeletal or extraskeletal sites. Liquid biopsies could improve and speed diagnosis, as they can better capture the disease heterogeneity while lowering patients' discomfort due to minimal invasiveness.
View Article and Find Full Text PDFArticle Synopsis
- Multiple myeloma is a common type of cancer affecting plasma cells, typically resulting in bone damage, while osteosclerotic myeloma is a rare form often linked to specific syndromes like POEMS.
- A case study of a 46-year-old woman revealed unusual osteosclerotic changes in her skull, prompting extensive imaging and testing that showed no signs of associated tumors or syndromes, but indicated plasma cell involvement.
- The diagnosis determined was monoclonal gammopathy of clinical significance with osteosclerosis, suggesting a unique form of myeloma that doesn't fit the typical presentation of the disease.
Background: Histiocytoses are rare disorders characterized by the accumulation of macrophages, dendritic cells, or monocyte-derived cells in various tissues and organs of children and adults, with a wide range of clinical manifestations, presentations, and histology. The histiocytoses are classified according to the WHO Classification, the last version of which was published in 2022, or according to the Histiocyte Society Classification, with the last version published in 2016.
Purpose: This text provides an overview of histiocytoses as described in the WHO Classification 2022.